Apimeds Pharmaceuticals US Inc

Important metrics include cash and short-term investments, total assets, current assets, total liabilities, current liabilities, long-term debt, shareholders' equity, retained earnings, inventory, receivables, working capital, current ratio, quick ratio, debt-to-equity ratio, and return on equity. Investors usually review these together rather than relying on one number.

Assets are resources the company owns or controls, such as cash, receivables, inventory, investments, and property. Liabilities are obligations the company owes, such as accounts payable, debt, leases, and taxes. Shareholders' equity is the residual value after liabilities are subtracted from assets.

Current assets and current liabilities are generally expected to be converted, used, paid, or settled within one year or one operating cycle. Non-current assets and non-current liabilities are longer-term items, such as property, long-term investments, deferred tax assets, long-term debt, and lease obligations.

In its most recent quarterly, Apimeds Pharmaceuticals US Inc had 979.53K in cash and cash equivalents.

Apimeds Pharmaceuticals US Inc reported 10.84M in total liabilities as of the latest reported quarter, including 10.71M in current liabilities and 129.45K in non-current liabilities.

As of the latest reported quarter, Apimeds Pharmaceuticals US Inc's total assets were 164.18M, consisting of 13.98M in current assets and 150.20M in non-current assets.

Apimeds Pharmaceuticals US Inc reported 153.35M in total shareholders' equity as of the latest reported quarter.